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Contemporary anticancer therapies have largely improved the outcome for children with cancer, especially for Acute
Lymphoblastic Leukemia (ALL). Actually, between 78% and 85% of patients achieve complete remission and are alive after 5 years
of therapy completion. However, as cure rates increase, new concerns about the late eﬀects of genotoxic treatment emerge, being
the risk of developing secondary neoplasias, the most serious life-threatening rising problem. In the present paper, we describe and
review the cytogenetic ﬁndings in peripheral lymphocytes from ALL survivors, and discuss aspects associated to the occurrence of
increased chromosome rearrangements in this growing cohort.
1.Introduction
Acute lymphoblastic leukemia (ALL) is the most common
malignancy in childhood and is associated with excellent
outcomes [1]. Currently, 80% of children with ALL treated
in modern centers are alive and disease-free at 5 years
[2]. The major contributors to this long-term survival are
the improvements in anticancer therapies. However, they
have implied the exposure of patients to combinations
of chemotherapy and, in some instances, preventive cra-
nial irradiation, which are well-recognized DNA-damaging
agents [3, 4]. Although most ALL survivors are at a lower
risk of developing a late eﬀect of therapy when compared
with survivors of other pediatric cancers, these children are
almost four times more likely than their siblings to develop
a severe or life-threatening chronic medical condition [5].
Recently, the number of patients with second malignancies
has increased among long-term survivors of pediatric ALL
[6–8]. There is compelling evidence that speciﬁc exposure
to radiation and chemotherapy are etiologic agents of
secondary neoplasia [9].
Chromosomal aberrations, sister chromatid exchanges
and micronuclei, which can be detected by cytogenetic anal-
ysis, have been used as important biomarkers of genotoxic
exposure; moreover, the relevance of increased frequency
of chromosome alterations as indicator of malignancy risk
is supported by epidemiological studies suggesting that a
high frequency of chromosomal aberrations is predictive of
an increased likelihood of cancer [10, 11]. The genotoxicity
of anticancer treatment has been evaluated by somatic cell
mutation assays, immediately or shortly after completion
of therapy. However, second malignancies in children usu-
ally occur several years after treatment [12]. Thus, the
cytogenetic analysis in peripheral lymphocytes from cancer
survivors,whohavebeenexposedtochemotherapy,provides
an opportunity to investigate the in vivo induction and2 Journal of Biomedicine and Biotechnology
persistence of genomic instability in humans, as well as to
evaluate the long-term eﬀects of cancer therapy.
In general, hematological malignancies are characterized
by recurrent chromosomal aberrations that lead to the
formation of gene fusions and the subsequent expression
of chimeric proteins with unique properties [13]. Various
gene fusions thought to be solely associated with leukemias
and lymphomas, such as t(12;21) ETV6/RUNX1, t(9;22)
BCR/ABL, t(14;18) IGH/BCL2,t ( 2 ; 5 )NPM-ALK, and MLL
duplications have been detected in normal individuals with
negative history of hematologic disorders [14, 15]. These
and other ﬁndings suggested that the measurement of gene
fusions in peripheral blood lymphocytes within a study
group may be used as a sensitive assay for the detection of
genomic instability, and may contribute to risk estimation
for the development of lymphoid malignancies [16, 17].
During the last years, our group has investigated the
existence of chromosome instability in peripheral lym-
phocytes from ALL survivors by means of ﬂuorescent in
situ hybridization (FISH) and molecular biology using
leukemia/lymphoma associated gene fusions as putative
markers. The proband group comprised 49 individuals aged
5to22years(a v erage=12),diagnosedandpreviouslytreated
for childhood ALL at the University Hospital (Faculty of
Medicine, Ribeir˜ ao Preto, University of S˜ ao Paulo, Brazil)
with combined modality treatment according to the Brazil-
ianGroupofPediatricLeukemiaTreatment(GBTLI)[18].In
this protocol, children were treated with a polychemother-
apeutic regimen that includes vincristine, dexamethasone,
daunorrubicin, L-asparaginase, prednisone, methotrexate,
cytosine arabinoside, cyclophosphamide, folinic acid, etopo-
side (VP-16), teniposide (VM-26), and 6 mercaptopurine. In
some cases prophylactic cranial and/or neuroaxis irradiation
was also included. The median event-free survival was 3.8
years(range5monthsto16years)andtherewerenorelapses.
Thecharacterizationofpatientswasdescribedintheworkby
Brassesco et al. [19].
Frequency of chromosomal aberrations were compared
to that observed for control nonsmoking healthy young
subjects, aged 18 to 22 years (average = 19.9), who were
not occupationally exposed, and had no history of prior
or concurrent malignancy. The study was approved by the
local Ethics Committee (HC-FMRP Ethics committee Proc.
1135/2000).
The results obtained for the diﬀerent markers are pooled
and described in the following subsections.
1.1. ETV6/RUNX1 Fusions. FISH for t(12;21) ETV6/RUNX1
was carried out using the LSI TEL/AML1 ES probe (Vysis,
Abbott Diagnostics, Maidenhead, United Kingdom) accord-
ing to the manufacturers’ instructions: 1000 interphase
nuclei were scored for each sample to determine the degree
of positivity for the fusion and the interphase signal patterns
of diﬀerent cell populations. Numbers of red-green fusion
signals were recorded corresponding to numbers of copies
ETV6/RUNX1, while numerous red and green signals corre-
spondingtoRUNX1 andETV6,respectively,werecollectively
considered as “extra signals.” Our study showed that ALL
Table 1: Mean frequency of ETV6/RUNX1 translocations and extra
signalsobtainedforALLsurvivors,healthyindividuals,andpatients
at the time of initial diagnosis [20].
Groups of individuals n
Translocations
%
(mean ± SD)
Extra Signals
%
(mean ±SD)
ALL survivors 12 3.20 ±1.19
∗ 0.76 ±0.68
Healthy individuals 12 1.02 ±0.40 0.44 ±0.43
ALL patients at diagnosis 8 0.57 ±2.17 0.53 ±1.71
∗Statistically diﬀerent, P<. 05.
Table 2: Translocation frequency for chromosome 12 obtained for
controls and childhood ALL survivors. Peripheral blood lympho-
cyte samples were collected from the patients at variable periods
after therapy conclusion.
Groups of individuals n Translocations % (mean ±SD)
ALL survivors 16 3.58 ±2.77
∗
Healthy individuals 13 1.57 ±1.65
∗Statistically diﬀerent, P<. 05.
survivors (n = 12) presented signiﬁcantly higher frequency
of ETV6/RUNX1 fusions (mean ± SD = 3.2 ± 1.19) than
those obtained for the control group (n = 12) (mean ±
SD = 1.02 ± 0.40). Extra signals were also detected for
both groups although frequencies were similar [20]. Gene
fusions incidence in lymphocytes from the group of patients
collected months or years after completion of therapy were
then compared with those obtained retrospectively for ﬁxed
bone marrow samples collected at the time of diagnosis.
Two out of ten samples studied were positive for the
t(12;21) at diagnosis, however, when these samples were
excluded from the statistical analysis, it was observed that
the frequency of aberrations obtained for treated patients
were signiﬁcantly higher than those in the untreated bone
marrow samples (mean ± SD = 0.57 ± 2.17) (Table 1).
More interesting, the fusion gene frequency in bone marrow
samples was similar to that observed for the control samples,
suggesting an inﬂuence of previous exposure to anticancer
drugs [20].
Also, sequential FISH was performed on lymphocytes
from ALL survivors, using chromosome speciﬁc library
probes for chromosome 12. For one thousand metaphases
scored, the frequency of translocations varied between zero
and 7.6 (mean ± SD = 3.58 ± 2.77) for the group of
patients while for the control group, the frequency was
between zero and 5.5/1000 metaphases (mean±SD = 1.57±
1.65) (Table 2). The statistical analysis revealed a signiﬁcant
diﬀerence (P = .02) between the patients and the control
group, in accordance with the previous results using locus
speciﬁcprobesforETV6/RUNX1,providingfurtherevidence
that chemotherapy had induced an increase in genomic
instability manifested as de novo chromosome aberrations
in peripheral blood lymphocytes sampled over years (most
cases) after therapy completion.Journal of Biomedicine and Biotechnology 3
Table 3: Mean frequency of MLL translocations and extra signals
obtained for ALL survivors and healthy individuals (taken from
[19]).
Groups of individuals n
Translocations
%
(mean ±SD)
Extra Signals
%
(mean ±SD)
Patients Treated with
topoisomerase II
inhibitors
15 0.13 ±0.14
∗ 0.28 ±0.28
Patients Treated without
topoisomerase II
inhibitors
31 0.09 ±0.117
∗ 0.16 ±0.168
Healthy individuals 49 0.04 ±0.065 0.18 ±0.198
∗Statistically diﬀerent, P<. 05.
For both types of probes the role of other covariates
such as age at initial diagnosis, inclusion of prophylac-
tic irradiation, and time passed after therapy conclusion
were statistically analyzed, showing that neither of these
parameters inﬂuenced the incidence of chromosomal aber-
rations.
1.2. MLL Fusions. FISH assessment for the presence of
aberrations involving the MLL gene (11q23) was performed
using the commercially available probes LSI MLL Break
Apart Rearrangement according to the protocol of the
manufacturer (Vysis). The expected signal pattern for a
normal cell nucleus is two green(yellow)orange signals. In
cells harboring MLL translocations, the green and orange
signals appear separated without the yellow intersection
allowing detection of any translocation at 11q23 irrespec-
tively of the partner involved. One thousand metaphases
from49ALLlong-termsurvivorsandthesamenumberfrom
control individuals were analyzed. Since MLL aberrations
are characteristic of secondary leukemias associated with
therapy with topoisomerase II inhibitors [21], the group
of patients was divided into two subgroups depending on
the inclusion or omission of VP-16 and/or VM-26 in the
treatment protocol. Our results showed signiﬁcant (P =
.007) diﬀerences between the frequency of translocations
observed for the groups of patients and controls. These
diﬀerences were also signiﬁcant (P = .006) when the groups
of patients (independently of the inclusion of VP-16 and/or
VM-26) and controls were compared, indicating that higher
frequency in the patients cohort might be associated with
the therapy with antitumoral drugs, independently of the
inclusion of topoisomerase II inhibitors. Extra signals were
also scored, however, their frequency did not diﬀer between
groups of patients and controls (Table 3)[ 19].
In parallel, MLL translocations were analyzed by Inverse-
PCR and identiﬁed by subsequent cloning and sequencing.
This methodology is speciﬁcally applicable for the identiﬁca-
tion of rearrangements with known 5  sequence, but whose
3  end could be represented by a myriad of translocation
partners as is the case of MLL fusions. Basically, DNA is
digestedbyproperrestrictionenzymes,circularizedandthen
ampliﬁed with divergent primers, detecting any segment
ﬂanking a known DNA sequence [22]. Individual PCR
products were cut, extracted from gels, and subsequently
cloned into the pGEM-T vector, further sequencing of PCR
products was achieved in order to conﬁrm the veracity of
the rearrangements. Eighty-one percent of patients (35 out
of 43) presented putative translocations; from those, 91%
corresponded with t(4;11)(q21;q23), while the other 9%
corresponded with t(X;11), t(8;11)(q23;q23), and t(11;16).
The control group was also analyzed by this technique
(n = 100), showing putative MLL rearrangements in 49%
of individuals. The presence of two or three putative
translocationswasstatisticallyhigherinthegroupofpatients
(P<. 05)whencomparedwiththecontrolgroup.Theresults
were also analyzed regarding the time in complete clinical
remission, which did not inﬂuence the results. Similarly, the
analysis considering other variables (sex, risk of relapse, and
inclusion of radiotherapy) did not inﬂuence the number of
translocations between patients [19].
1.3. IGH/CCND1 Fusions. Locus-speciﬁc identiﬁer dual-
color directly labeled IGH(spectrum Green)/CCND1
(Spectrum-Orange) (Vysis) probes were used for detecting
the t(11;14)(q13;q32) originated by the juxtaposition of the
immunoglobulin gene (IGH) at 14q32 with the CCND1
gene (cyclin D1, BCL1,o rPRAD1), localized at 11q13. The
expected signal pattern for a nucleus with t(11;14) is one
green (normal IGH), one red (normal CCND1), and two
red(yellow)green signals (1G1R2Y), due to the fact that the
break usually occurs in the middle of the probe marked
region, resulting in two fragments of each gene, however,
these fragments can be lost, or extra signals of each gene
can be detected, resulting in diﬀerent patterns of signals
(2G1R1Y, 1G2R1Y; or 3G2R, 2G3R, in the case of an extra
signal). At least 1000 interphase nuclei were analyzed per
individual. The group of patients in complete remission
(n = 14) presented frequency of fusions varying between
0.09 and 0.49/100 cells. These values were signiﬁcantly
higher (P = .0126) compared with those observed for
the control group (n = 15), which varied from 0 to 0.29
fusions/100 cells. The probes also allowed the detection of
extra signals for both genes, with frequency varying from
0.09 to 0.69 signals/100 cells for patients and from 0 to
0.48 signals/100 cells for controls. As seen for IGH/CCND1
fusions, the frequency of extra signals presented by the group
of patients in complete remission were signiﬁcantly higher
(P = .0282) than those presented by healthy individuals.
When the inclusion of preventive cranial irradiation was
considered no diﬀerences in IGH/CCND1 fusions frequency
and extra signals were observed between of patients in
complete remission and the control group.
A retrospective analysis was also carried out with
sequential bone marrow samples collected at the moment
of diagnosis from nine of the fourteen ALL patients, with
the aim of determining whether the fusion IGH/CCND1 was
already present before treatment. The fusion appeared with
frequency varying from 0 to 0.41 IGH/CCND1 fusions/100
cells and from 0 to 2.6 extra signals/100 cells. Interest-
ingly, among these samples, only one patient showed high4 Journal of Biomedicine and Biotechnology
Table 4: Mean frequency of IGH/CCND1 translocations and extra
signalsobtainedforALLsurvivors,healthyindividuals,andpatients
at the time of initial diagnosis.
Groups of individuals n
Translocations
%
(mean ±SD)
Extra Signals
%
(mean ±SD)
ALL survivors 14 0.19 ±0.10
∗ 0.29 ±0.17
Healthy individuals 15 0.09 ±0.06 0.19 ±0.15
ALL patients at diagnosis 9 0.19 ±0.18 0.39 ±0.77
∗Statistically diﬀerent, P<. 05.
Table 5: Mean frequency of BCR/ABL translocations and extra
signalsobtainedforALLsurvivors,healthyindividuals,andpatients
at the time of initial diagnosis.
Groups of individuals n
Translocations
%
(mean ±SD)
Extra Signals
%
(mean ±SD)
ALL survivors 8 0.99 ±0.55 1.19 ±0.97
Healthy individuals 8 0.49 ±0.53 0.25 ±0.27
ALL patients at diagnosis 4 1.20 ±0.26
∗ 1.80 ±6.18
∗Statistically diﬀerent, P<. 05.
frequency of extra signals (2.6/100 cells), which might
represent rearrangements of the IGH gene with another
partner (Table 4).
The analysis of other variables such as risk of relapse and
inclusion of radiotherapy did not show diﬀerences in the
frequency of IGH/CCND1 translocations between patients.
1.4. BCR/ABL1 Fusions. FISH for t(9;22) that juxtaposes the
ABL gene at 9q34 and the BCR gene at 22q11.2 was carried
outusingtheLSIBCR/ABLESprobe(Vysis)accordingtothe
manufacturers’ instructions. The hybridization pattern for
these probes is two orange and two green signals for normal
cells (2O2G). Cells with t(9;22) involving the M-bcr show
one large orange, one smaller orange (ES), and one fused
orange/green signal (2O1G1F), while for translocations
involving the minor breakpoint (m-bcr) appear as one
orange, one green, and two fusion signals (1O1G2F) are
observed. In this case, samples from 8 ALL survivors and the
samenumberofcontrolindividualswereanalyzed.Thecyto-
genetic analysis of 1000 metaphases showed translocation
frequency varying from 0.236 to 1.627 for treated patients
(mean±SD = 0.99±0.55) and between zero and 1.30 for the
control group (mean±SD = 0.49±0.53). Extra signals were
also detected with frequency varying from 0.59 to 3.69 and
zero to 0.9 for patients and controls, respectively. However,
the statistical analysis was unable to detect diﬀerences for
translocations and extra signals between the studied groups
(P>. 05). A retrospective analysis with sequential samples
obtainedatthetimeofdiagnosiswasalsoperformed(n = 4).
Translocation incidence varied from 0.8 to 1.54, while extra
signals varied from 1.10 to 15.56; however, this group was
not big enough to establish comparisons with the frequency
observed the other groups (Table 5).
2. Discussion
Since 1970, the number of cancer survivors in developed
countries has tripled and is growing by 2% each year [23].
Cancer treatments have become much more aggressive as
new agents and better supportive therapies are in constant
development. The long-term consequences of cancer cure
may be signiﬁcant for the patients who often experience
physical or physiological late eﬀects secondary to their
previous cancer treatment [4]. Many of these eﬀects may
notoccurorbecomeclinicallysymptomaticuntilmanyyears
after completion of therapy, though, the development of a
second malignant neoplasm can be the most devastating late
eﬀect of cancer treatment.
Childhood-cancer survivors present a higher risk of
developing secondary malignancies [24] which characterize
the leading cause of death among this cohort [25]. The
time of occurrence has not been established, but in gen-
eral between 3 and 12 percent of the patients develop a
subsequent cancer within the ﬁrst 20 years after therapy
conclusion. The most widely recognized treatment-related
risk factors are alkylating agents and topoisomerase II
inhibitors (epipodophyllotoxins and anthracyclines). The
magnitude of the risk associated with these factors depends
on several variables such as initial diagnosis, age at diagnosis,
the administration schedule, concomitant medications, and
genetic predisposition among others [26]. Exposure to
alkylating agents or topoisomerase inhibitors during therapy
has also been associated with higher risk of developing
secondary leukemia among ALL cured patients [27].
Treatment of pediatric ALL consists of several doses of
anticancer drugs given weekly or daily for 2-3 years [28].
These drugs cause DNA breaks, facilitating the formation
of chromosome rearrangements [4, 29]. Thus, like de
novo leukemias, therapy-related hematological disorders are
commonly associated with recurrent aberrations [7]. Chro-
mosome(s) 7 and/or 5 monosomies or deletions are typical
of alkylating agent-induced AML, while balanced translo-
cations involving chromosome bands 11q23 and 21q22 are
associated to previous therapy with DNA-topoisomerase II
inhibitors [23] which usually lead to the formation of gene
fusions involving MLL [21]a n dRUNX1 [30], respectively.
Translocations involving the latter have been identiﬁed
in therapy-related secondary leukemias [31]w i t hp a r t n e r s
such as ETO (Eight Twenty One) and EVI1 (Ecotropic
Viral Integration site 1 oncogene) [32]. Other numerical
and structural rearrangements have also been described in
diﬀerent secondary therapy-related neoplasms although at
lower frequency, including t(3;21) [33], t(9;22) BCR-ABL1
[34], t(1;21), t(3;21), t(14;21), t(15;21), and t(17;21) [35].
In the present paper, we pooled a screening for structural
aberrations (ETV6/RUNX1, MLL fusions, IGH/CCND1, and
BCR/ABL1)inALLlong-termsurvivors,comparedwithcon-
trol individuals, as evaluated by FISH on interphase nuclei
using a speciﬁc commercial DNA probes. As shown in Fig-
ure 1, all the markers studied showed higher frequency when
compared to the control group, thus providing evidence that
chemotherapy could have induced an increase in genomic
instability manifested as de novo chromosome aberrationsJournal of Biomedicine and Biotechnology 5
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Figure 1: Mean frequency of gene fusions in peripheral lympho-
cytes from ALL survivors analyzed months or year(s) after therapy
completion (black boxes) and healthy donors (white boxes). In the
case of MLL fusions the group of survivors was subdivided into
patients treated with topoisomerase II inhibitors (grey box) and
patientstreatedwithouttheinclusionofsuchdrugsinthetreatment
protocol (black box). ∗P<. 05. Data for ETV6/RUNX1 and MLL
was taken from Brassesco et al. [20] and [19], respectively.
in peripheral blood lymphocytes sampled over years (most
cases) after therapy completion. The diﬀerences between
groupswerestatisticallydiﬀerentfortheETV6/RUNX1,MLL
fusions,andIGH/CCND1markers.InthecaseofBCR/ABL1,
although the rearrangement appeared at higher frequency
in ALL survivors, the study groups analyzed were not big
enough for the proper comparison.
Mutational studies at the FMS proto-oncogene demon-
strated the acquisition of mutation in patients treated
with alkylating agents and radiation [3]. The absence of
such mutations in biopsies at initial diagnosis suggested
that they were somatically acquired after treatment and
they appeared with increased frequency in relation to the
normal population not exposed to cytotoxic drugs.Similarly,
studies of HRPT (hypoxanthine phosphoribosyltransferase)
mutations demonstrated signiﬁcantly elevated frequency in
patients treated for pre-B ALL, even two years after therapy
completion [12].
Furthermore, rearrangements at 11q23 have been found
during treatment of primary cancer, as observed in case of
t(11;17) MLL/GASP [36]. Other chromosomal rearrange-
m e n t ss u c ha sPML-RARA, CBFB-MYH11, MLL-MLLT1,
and BCR-ABL1 have also been observed in Non-Hodgkin
Lymphoma patients after high-dose therapy [37]d e m o n -
strating the susceptibility of speciﬁc genes to mutagenic or
carcinogenic agents [38].
Indeed, although translocations might be formed by
diﬀerent mechanisms, several studies have mapped speciﬁc
chromatinstructuralelements,suchasinvivotopoisomerase
II (topo II) cleavage sites, DNAse I hypersensitive sites
and scaﬀold attachment regions (SARs) in the breakpoint
regions of relevant genes (including MLL, AF4, AF9, AML1,
ETO, CBFB, MYHI1, PML, RARA, TEL, E2A, PBX1, BCR,
and ABL) that are probably associated with preferential
breakage after exposure to damage including topoisomerase
II inhibitors [39]. In most cases, the breakpoints do not
colocalize exactly with topoisomerase II cleavage sites, but
map close to or at a variable distance from them. After the
induction of DNA cleavage at these sites, the religation of the
double strand breaks occurs by the action of complex DNA
repair mechanisms, mainly nonhomologous end joining
(NHEJ) [39].
Other mechanisms such as illegitimate recombination
mediated by Alu repeats and long interspersed nuclear
elements (LINEs) have been proposed to participate in
the formation of gene fusions [40, 41]. Illegitimate V(D)J
recombination have also been described, with site-speciﬁc
DNA cleavage at heptamer/nonamer signal sequences with
the IGH variable region or the TCR binding region arranged
in juxtaposition with other tumor suppressors genes or
oncogenes like MYC or CCND1 in lymphoid malignancies
[42, 43]; besides several studies have demonstrated that the
exposure to DNA-damaging agents in vitro increase V(D)J
rearrangements frequency at cryptic signal sequences other
than IGH and TCR loci [44, 45].
In addition, the induction of leukemia-associated fusion
g e n e ss u c ha st ( 8 ; 2 1 )AML1/ETO, t(9;22) BCR/ABL,a n d
t(6;9) DEK/CAM (associated with AML and CML) by high
doses of ionizing radiation has been reported in vitro [46]
and in patients accidentally exposed to ionizing radiation
[47, 48].
According to the literature, the inclusion of radio-
therapy in diﬀerent treatment regimens is associated with
an increase (2-3 times) in the risk of developing solid
tumors [49]. Among the ALL survivors analyzed in the
present study, 13 (28%) were submitted to diﬀerent doses
of cranial or neuroaxis γ-radiation. However, these patients
did not show increased translocation frequency (for any
marker) compared with patients who were only treated with
chemotherapy.
Several authors have demonstrated that the production
ofunstableaberrations(ringsanddicentrics)afterradiother-
apy decreases with time, and sequential cytogenetic studies
performed on peripheral lymphocytes taken from patients
treated for diﬀerent cancers showed a constant decline
in chromosomal aberrations [50]. M’kacher et al. [51]
demonstrated by chromosome painting that after an initial
decrease for up to 6 months after treatment, the frequency of
complex rearrangements remained constant for up to 2 years
during the follow-up of Hodgkin’s lymphoma survivors. In
ourstudy,theperiodaftertherapyconclusionvariedbetween
5and192months(medianevent-freesurvivalwas3.8years),
however, the statistical analysis did not show any signiﬁcant
relationship between the frequency of translocations for any
of the markers and time passed after therapy conclusion.
In the last years, the treatment directed to the central
nervoussystemhassuﬀeredmodiﬁcationswithatendencyof
lowering doses and the irradiated area, using dose rationing
regimens [52]. In general, protocols have eliminated radi-
ation to the spine, decreased cranial irradiation doses or
replaced them with intrathecal and/or systemic drugs such
ashigh-dosemethotrexate[5].Currently,ALLpatientsatour
service are submitted to doses of 18Gy (classiﬁed as standard
risk of relapse) and 24Gy (higher risk of relapse), according
to the GBTLI protocol [18]. Nonetheless, several epidemio-
logical studies have demonstrated that the risk of t-LMAs or
t-MDSs is predominantly associated with chemotherapy and
nottoradiotherapy,principallyemphasizingtherelationship6 Journal of Biomedicine and Biotechnology
between speciﬁc drugs and chromosome rearrangements
[53], as veriﬁed for topoisomerase II inhibitors associated to
11q23 aberrations.
When considering the MLL aberrations, the group of
patients presented signiﬁcantly higher aberration frequency
when compared to control individuals, although such diﬀer-
ences were independent of the inclusion of VP-16 or VM-26
in the treatment protocol. Some studies have demonstrated
that concomitant adjuvant chemotherapy (such as asparag-
inase, doxorubicin, cyclophosphamide) or antimetabolites
(such as mercaptopurine or methotrexate) administration,
increase the risk of secondary leukemia [26].
Also, individual predisposing factors, including poly-
morphisms of detoxiﬁcation and DNA-repair enzymes that,
for instance, reduce the enzymatic activity of thiopurine
methyltransferase, a variant of CYP3A that aﬀects pro-
duction of a DNA-damaging metabolite of epipodophyl-
lotoxin. Other polymorphisms in glutathione S-transferase
and NAD(P)H:quinine oxidoreductase (NQO1)a r ea sw e l l
associated with increased risk of secondary leukemia after
chemotherapy [23].
Since strategies in cancer treatment are continuously
evolving, the investigation of rearrangements that could
represent a risk factor for the development of secondary
neoplasiasisimportantforcancersurvivors.Individualswith
a history of childhood cancer have 10–20 fold greater risk
of developing a secondary malignant neoplasm within the
ﬁrst 20 years after treatment [54] turning therapy-related
neoplasias a worldwide problem of major proportions [55,
56].
Between 10% and 20% of acute leukemia patients
reported in various series have developed a secondary cancer
following previous therapy, and considering cured ALL
patients, a greater frequency of neoplasias has been observed
when compared to normal individuals [8, 57, 58]. None
of our patients developed a secondary cancer over 5 years
of clinical follow-up. Yet, even though the chromosome
aberrations detected in this study appear at low frequency
in ALL survivors, there were signiﬁcant diﬀerences when
compared to the control group.
Although some studies have demonstrated that some of
these fusion genes can lead to a greater cellular proliferation,
like BCR/ABL, ETV6/RUNX1, IGH/BCL-2, among others,
such alterations by themselves are not enough for tumori-
genesis, and secondary multiple genetic alterations are
necessary[59–61].Recentstudieshavealsodemonstratedthe
presence of leukemia-related chromosomal translocations in
normal individuals, such as t(14;18) IGH/BCL2 [62–64]a n d
t(9;22) [65], t(12;21) ETV6/RUNX1 [14], t(11;14)(p13;q11)
LMO2/TCR and t(7;14)(q34;q11) TCR/TAL2 [42], t(15;17)
PML/RARA [66], and MLL partial duplications [15, 67],
indicatingthatthepresenceofsuchtranslocationspersedoes
not deﬁne an apparent clinical disease.
Although, it cannot be assumed that the observed
therapy-induced genetic damage in the group of ALL
survivors is predictive of an increased risk of developing
secondary neoplasias, cytogenetic surveillance should be
considered to evaluate the occurrence of persistent genome
instability in these patients, as well as to associate particular
evolving genomic aberrations to the potential risk of sec-
ondary malignancies in this cohort.
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